Content area

|
|

Medicinsk behandling af fedme

Medicinsk behandling af svær overvægt.
Forfatter(e)
Jens Meldgaard Bruun Medicinsk Afdeling M, Regionshospitalet Randers Ugeskr Læger 2016;178:V06160406
Reference: 
Ugeskr Læger 2016;178:V06160406
Blad nummer: 
Sidetal: 
2-6
Pharmacotherapy for obesity
Obesity is a chronic condition, which is why pharmaco­therapy can be considered, if lifestyle modification (hypo­caloric diet/exercise) does not result in a weight loss of at least 5%. Pharmacotherapy is indicated, if an individual has a BMI > 30 kg/m2 or a BMI > 27 kg/m2 and concomitant disease (e.g. Type 2 diabetes), and can be liraglutide (3 mg) or orlistat (120 mg/60 mg). Choice of treatment must be based on patient preferences and clinical situation, side effects, contraindications and financial considerations. Weight loss of < 5% (about 4-5 kg) after 12 weeks should lead to cessation of the treatment.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Pedram Kazemi-Esfarjani | 28/11
2 kommentarer
af David McWhan | 27/11
4 kommentarer
af Ulf Bern Jensen | 24/11
2 kommentarer
af Bodil Marie Nielsen | 24/11
2 kommentarer
af Jan Nielsen | 23/11
1 Kommentar
af Toke Seierøe Barfod | 23/11
2 kommentarer
af Thorkild I.A. Sørensen | 20/11
1 Kommentar
af Kim Varming | 20/11
1 Kommentar
af Niels Holmark Andersen | 20/11
1 Kommentar